Related references
Note: Only part of the references are listed.Acute Lymphoblastic Leukemia, Version 2.2021
Patrick A. Brown et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
A Systematic Review of Discrete Choice Experiments in Oncology Treatments
Hannah Collacott et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2021)
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events From Mechanism to Patient Care
Ali Manouchehri et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
Santa Cirmi et al.
CANCERS (2020)
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group
Kevin Marsh et al.
VALUE IN HEALTH (2020)
Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia
Han-Seung Park
BLOOD RESEARCH (2020)
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Moshe Yair Levy et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Discrete Choice Experiments in Health Economics: Past, Present and Future
Vikas Soekhai et al.
PHARMACOECONOMICS (2019)
Did You Miss Something? Inattentive Respondents in Discrete Choice Experiments
Erlend Dancke Sandorf
ENVIRONMENTAL & RESOURCE ECONOMICS (2019)
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia A Population-Based Cohort Study
Torsten Dahlen et al.
ANNALS OF INTERNAL MEDICINE (2016)
Hyper-CVAD Plus Ponatinib Versus Hyper-CVAD Plus Dasatinib as Frontline Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Koji Sasaki et al.
CANCER (2016)
Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective
Axel C. Muehlbacher et al.
VALUE IN HEALTH (2016)
Challenges in Measuring Cost and Value in Oncology: Making It Personal
Peter P. Yu
VALUE IN HEALTH (2016)
Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective
F. Reed Johnson et al.
VALUE IN HEALTH (2016)
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Yves Chalandon et al.
BLOOD (2015)
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Farhad Ravandi et al.
CANCER (2015)
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Peter Valent et al.
BLOOD (2015)
The use of discrete choice experiments to inform health workforce policy: a systematic review
Kate L. Mandeville et al.
BMC HEALTH SERVICES RESEARCH (2014)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force
F. Reed Johnson et al.
VALUE IN HEALTH (2013)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
E. Jabbour et al.
LEUKEMIA (2011)
Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
John F. P. Bridges et al.
VALUE IN HEALTH (2011)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Share Paper
